GENITOURINARY CANCERS

Three-year data showed durable clinical activity with nadofaragene firadenovec-vncg in patients with high-risk, BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ with or without papillary tumors.

The gene therapy, nadofaragene firadenovec-vncg, is now fully available across the United States for patients with this aggressive bladder cancer.

In season 5, episode 1 of Targeted Talks, Badrinath Konety, MD, delves into the critical topic of prostate cancer screening and discusses some of the recent advancements in the prostate cancer space.

Rucaparib showed a significant improvement in progression-free survival compared with docetaxel in metastatic castration- resistant prostate cancer.

TAR-200, a novel targeted therapy, has been granted breakthrough therapy designation by the FDA in high-risk non-muscle-invasive bladder cancer that is unresponsive to Bacillus Calmette-Guérin.

No serious adverse events or dose-limiting toxicities were observed in the phase 1/2 trial of the antibody drug conjugate ARX517.

Neal Shore, MD, FACS, discussed the phase 3 EMBARK trial and what the FDA approval of enzalutamide means for the prostate cancer treatment landscape.

An analysis, based on data from the JAVELIN 100 Bladder trial, found the NCCN/FACT Bladder Symptom Index-18 for assessing quality-of-life in patients with advanced urothelial carcinoma to be reliable and valid.

In patients with metastatic castration-resistant prostate cancer of the adenocarcinoma phenotype, the combination of BXCL701 and pembrolizumab led to a median overall survival of 15.5 months.

The combination of SRK-181 and pembrolizumab demonstrated improvements in objective response rate among patients with clear cell renal cell carcinoma in a phase 1 proof-of-concept study.

Shifting their focus to metastatic bladder cancer, the Oncology Brothers and Rana McKay, MD, reflect on data from EV-302 and consider how enfortumab vedotin + pembrolizumab has shifted the treatment landscape.

Key opinion leader Rana McKay, MD, joins the Oncology Brothers Rahul Gosain, MD, and Rohit Gosain, MD, to review updated data in GU cancer from ESMO 2023, starting with TAR-200 monotherapy in patients with NMIBC and the SunRISE-1 trial.

With an investigational new drug granted to ZH9 by the FDA, a clinical development program for the treatment of patients with non-muscle invasive bladder cancer can be initiated.

During a Targeted Oncology™ Case-Based Roundtable™ event, Benjamin Garmezy, MD, and participants discussed their takeaways from the phase 3 trials of immunotherapy and tyrosine kinase inhibitors in frontline renal cell carcinoma. This is the second article based on this event.

In the KEYNOTE-564 trial, patients with renal cell carcinoma who had a nephrectomy achieved improved overall survival rates vs placebo when treated with adjuvant pembrolizumab.

In a phase 2 trial, BXCL701 and pembrolizumab showed a significant increase in median overall survival time for patients with small cell neuroendocrine prostate cancer.

Arlene Siefker-Radtke, MD, highlights the ongoing quest for improved treatment options in metastatic urothelial cancer, emphasizing the role of clinical trials and novel agents in addressing unmet needs.

Expert perspective on the impact of neuropathy on treatment choices in urothelial cancer, providing insight into identifying and managing peripheral neuropathy and exploring suitable treatment options.

Arlene Siefker-Radtke, MD, delves into the complexities of managing progressive disease in metastatic urothelial cancer, outlining considerations for immune checkpoint inhibitors, antibody drug conjugates, and other targeted therapies.

Diverse approaches to frontline treatment for metastatic urothelial cancer, including eligibility for cisplatin-based chemotherapy, alternative regimens, and the impact of drug shortages on treatment decisions.

Arlene Siefker-Radtke, MD, emphasizes the importance of early mutation profiling in metastatic urothelial cancer and highlights the potential for targeted agents and clinical trials to improve treatment outcomes.

The evolving role of biomarker testing, including PD-L1 expression and mutations like FGFR3, in guiding treatment decisions for urothelial cancer patients, shedding light on their clinical significance and potential impact on therapeutic choices.

Expert insight into the complexities of managing metastatic urothelial cancer in geriatric patients with comorbidities, highlighting the importance of aggressive therapy in improving survival outcomes.

Arlene Siefker-Radtke, MD, discusses the nuanced treatment journey of a 73-year-old man with metastatic bladder cancer, highlighting the challenges and evolving strategies in his case.

Roby Thomas, MD discusses chemotherapy shortages and the impact these shortages have had on oncology research.